Want to see DFTX full AI Analyst Report?

Definium Therapeutics (DFTX) Stock Forecast & Price Target

2,347 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

DFTX Analyst Ratings

Strong Buy

12 Buy

0 Hold

0 Sell

Based on 12 analysts giving stock ratings to

Definium

Therapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

DFTX Stock 12 Month Forecast

Average Price Target

$54.33

▲(139.56% Upside)

Based on 12 Wall Street analysts offering 12 month price targets for Definium Therapeutics in the last 3 months. The average price target is $54.33 with a high forecast of $74.00 and a low forecast of $30.00. The average price target represents a 139.56% change from the last price of $22.68.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"5":"$5","40":"$40","75":"$75","22.5":"$22.5","57.5":"$57.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":74,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$74.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":54.333333333333336,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$54.33</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":30,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$30.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[5,22.5,40,57.5,75],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2025","6":"Dec<br/>2025","9":"Mar<br/>2026","12":"Jun<br/>2026","25":"Jun<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,24.06,27.90153846153846,31.74307692307692,35.58461538461538,39.426153846153845,43.26769230769231,47.10923076923076,50.950769230769225,54.79230769230769,58.63384615384615,62.47538461538461,66.31692307692308,70.15846153846154,{"y":74,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,24.06,26.388717948717947,28.717435897435898,31.046153846153846,33.374871794871794,35.703589743589745,38.03230769230769,40.36102564102564,42.689743589743586,45.01846153846154,47.34717948717949,49.67589743589744,52.004615384615384,{"y":54.333333333333336,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,24.06,24.516923076923074,24.973846153846154,25.43076923076923,25.88769230769231,26.344615384615384,26.80153846153846,27.25846153846154,27.715384615384615,28.17230769230769,28.62923076923077,29.086153846153845,29.543076923076924,{"y":30,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":7.48,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.68,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.44,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.13,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.33,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.2,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.26,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.39,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.23,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.18,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.6,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.7,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.06,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 52,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$74.00

Average Price Target$54.33

Lowest Price Target$30.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Paul Matteis

Stifel Nicolaus

$30

Buy

32.28%

Upside

Reiterated

06/29/26

Analysts Are Bullish on Top Healthcare Stocks: Crinetics Pharmaceuticals (CRNX), Definium Therapeutics (DFTX)

Sumant Kulkarni

Canaccord Genuity

$60→$58

Buy

155.73%

Upside

Reiterated

06/29/26

Analysts Are Bullish on Top Healthcare Stocks: Definium Therapeutics (DFTX), Atricure (ATRC)

Francois Brisebois

LifeSci Capital

$44→$63

Buy

177.78%

Upside

Reiterated

06/27/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Ami Fadia

Needham

$38→$50

Buy

120.46%

Upside

Assigned

06/23/26

Analysts Are Bullish on These Healthcare Stocks: Definium Therapeutics (DFTX), Apogee Therapeutics (APGE)

Patrick Trucchio

H.C. Wainwright

$70

Buy

208.64%

Upside

Reiterated

06/23/26

Definium: Buy Rating Reiterated on Strong EMERGE Phase 3 Data; $70 Price Target Maintained

Justin Walsh

JonesTrading

$61→$74

Buy

226.28%

Upside

Reiterated

06/23/26

Analysts Offer Insights on Healthcare Companies: Definium Therapeutics (NASDAQ: DFTX), TScan Therapeutics (NASDAQ: TCRX) and PACS Group Inc (NYSE: PACS)

Christopher Chen

Robert W. Baird

Not Ranked

Robert W. Baird

$37→$57

Buy

151.32%

Upside

Reiterated

06/23/26

Definium Therapeutics price target raised to $57 from $37 at BairdDefinium Therapeutics price target raised to $57 from $37 at Baird

Michael Okunewitch

Maxim Group

$40→$50

Buy

120.46%

Upside

Assigned

06/23/26

Analyst Raises 12‑Month Target and Reiterates Buy on Definium After Best-in-Class MDD Trial Results and Reduced Risk Adjustment

Jay Olson

Oppenheimer

$40→$60

Buy

164.55%

Upside

Reiterated

06/22/26

Definium Therapeutics price target raised to $60 from $40 at OppenheimerDefinium Therapeutics price target raised to $60 from $40 at Oppenheimer

Andrew Tsai

Jefferies

$30→$35

Buy

54.32%

Upside

Assigned

06/22/26

Definium can climb 50%-100% after 'robust' MDD data, says JefferiesDefinium can climb 50%-100% after 'robust' MDD data, says Jefferies

Brian Abrahams

RBC Capital

$36→$57

Buy

151.32%

Upside

Reiterated

06/22/26

RBC Capital says would buy Definium Therapeutics after Phase III dataRBC Capital says would buy Definium Therapeutics after Phase III data

David Amsellem

Piper Sandler

$49→$48

Buy

111.64%

Upside

Reiterated

05/08/26

Definium Therapeutics price target lowered to $48 from $49 at Piper SandlerDefinium Therapeutics price target lowered to $48 from $49 at Piper Sandler

Gavin Clark-Gartner

Evercore ISI

$24→$26

Buy

14.64%

Upside

Reiterated

03/02/26

Evercore ISI Sticks to Their Buy Rating for Definium Therapeutics (DFTX)

Rudy Li

Wolfe Research

$25

Buy

10.23%

Upside

Initiated

02/23/26

Definium Therapeutics initiated with an Outperform at Wolfe ResearchDefinium Therapeutics initiated with an Outperform at Wolfe Research

Jason Wittes

Roth MKM

$36

Buy

58.73%

Upside

Reiterated

08/04/25

Analysts Are Bullish on Top Healthcare Stocks: Mind Medicine (MNMD), Axsome Therapeutics (AXSM)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Paul Matteis

Stifel Nicolaus

$30

Buy

32.28%

Upside

Reiterated

06/29/26

Analysts Are Bullish on Top Healthcare Stocks: Crinetics Pharmaceuticals (CRNX), Definium Therapeutics (DFTX)

Sumant Kulkarni

Canaccord Genuity

$60→$58

Buy

155.73%

Upside

Reiterated

06/29/26

Analysts Are Bullish on Top Healthcare Stocks: Definium Therapeutics (DFTX), Atricure (ATRC)

Francois Brisebois

LifeSci Capital

$44→$63

Buy

177.78%

Upside

Reiterated

06/27/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Ami Fadia

Needham

$38→$50

Buy

120.46%

Upside

Assigned

06/23/26

Analysts Are Bullish on These Healthcare Stocks: Definium Therapeutics (DFTX), Apogee Therapeutics (APGE)

Patrick Trucchio

H.C. Wainwright

$70

Buy

208.64%

Upside

Reiterated

06/23/26

Definium: Buy Rating Reiterated on Strong EMERGE Phase 3 Data; $70 Price Target Maintained

Justin Walsh

JonesTrading

$61→$74

Buy

226.28%

Upside

Reiterated

06/23/26

Analysts Offer Insights on Healthcare Companies: Definium Therapeutics (NASDAQ: DFTX), TScan Therapeutics (NASDAQ: TCRX) and PACS Group Inc (NYSE: PACS)

Christopher Chen

Robert W. Baird

Not Ranked

Robert W. Baird

$37→$57

Buy

151.32%

Upside

Reiterated

06/23/26

Definium Therapeutics price target raised to $57 from $37 at BairdDefinium Therapeutics price target raised to $57 from $37 at Baird

Michael Okunewitch

Maxim Group

$40→$50

Buy

120.46%

Upside

Assigned

06/23/26

Analyst Raises 12‑Month Target and Reiterates Buy on Definium After Best-in-Class MDD Trial Results and Reduced Risk Adjustment

Jay Olson

Oppenheimer

$40→$60

Buy

164.55%

Upside

Reiterated

06/22/26

Definium Therapeutics price target raised to $60 from $40 at OppenheimerDefinium Therapeutics price target raised to $60 from $40 at Oppenheimer

Andrew Tsai

Jefferies

$30→$35

Buy

54.32%

Upside

Assigned

06/22/26

Definium can climb 50%-100% after 'robust' MDD data, says JefferiesDefinium can climb 50%-100% after 'robust' MDD data, says Jefferies

Brian Abrahams

RBC Capital

$36→$57

Buy

151.32%

Upside

Reiterated

06/22/26

RBC Capital says would buy Definium Therapeutics after Phase III dataRBC Capital says would buy Definium Therapeutics after Phase III data

David Amsellem

Piper Sandler

$49→$48

Buy

111.64%

Upside

Reiterated

05/08/26

Definium Therapeutics price target lowered to $48 from $49 at Piper SandlerDefinium Therapeutics price target lowered to $48 from $49 at Piper Sandler

Gavin Clark-Gartner

Evercore ISI

$24→$26

Buy

14.64%

Upside

Reiterated

03/02/26

Evercore ISI Sticks to Their Buy Rating for Definium Therapeutics (DFTX)

Rudy Li

Wolfe Research

$25

Buy

10.23%

Upside

Initiated

02/23/26

Definium Therapeutics initiated with an Outperform at Wolfe ResearchDefinium Therapeutics initiated with an Outperform at Wolfe Research

Jason Wittes

Roth MKM

$36

Buy

58.73%

Upside

Reiterated

08/04/25

Analysts Are Bullish on Top Healthcare Stocks: Mind Medicine (MNMD), Axsome Therapeutics (AXSM)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

TRAXFirst Tracks Biotherapeutics Inc

EVMNEvommune, Inc.

MPLTMapLight Therapeutics, Inc.

MAZEMaze Therapeutics, Inc.

AAPGAscentage Pharma Group International Unsponsored ADR

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Definium Therapeutics

3 Months

Sumant KulkarniCanaccord Genuity

Success Rate

11/13 ratings generated profit

Average Return

+44.58%

Copying Sumant Kulkarni's trades and holding each position for 3 Months would result in 84.62% of your transactions generating a profit, with an average return of +44.58% per trade.

1 Year

Patrick TrucchioH.C. Wainwright

Success Rate

16/18 ratings generated profit

Average Return

+142.91%

Copying Patrick Trucchio's trades and holding each position for 1 Year would result in 88.89% of your transactions generating a profit, with an average return of +142.91% per trade.

2 Years

Patrick TrucchioH.C. Wainwright

Success Rate

18/18 ratings generated profit

Average Return

+329.62%

Copying Patrick Trucchio's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +329.62% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

DFTX Analyst Recommendation Trends

Rating

Feb 26

Mar 26

Apr 26

May 26

Jun 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, DFTX has received 52 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. DFTX average Analyst price target in the past 3 months is 54.33.

Each month's total comprises the sum of three months' worth of ratings.

DFTX Financial Forecast

DFTX Earnings Forecast

Next quarter’s earnings estimate for DFTX is -$0.56 with a range of -$0.72 to -$0.44. The previous quarter’s EPS was -$0.71. DFTX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year DFTX has Performed in-line its overall industry.

No data currently available

DFTX Sales Forecast

Next quarter’s sales forecast for DFTX is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. DFTX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year DFTX has Performed in-line its overall industry.

DFTX Stock Forecast FAQ

What is DFTX’s average 12-month price target, according to analysts?

Based on analyst ratings, Definium Therapeutics, Inc.’s 12-month average price target is 54.33.

What is DFTX’s upside potential, based on the analysts’ average price target?

Definium Therapeutics, Inc. has 139.56% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is DFTX a Buy, Sell or Hold?

Definium Therapeutics, Inc. has a consensus rating of Strong Buy which is based on 12 buy ratings, 0 hold ratings and 0 sell ratings.

What is Definium Therapeutics, Inc.’s price target?

The average price target for Definium Therapeutics, Inc. is 54.33. This is based on 12 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $74.00 ,the lowest forecast is $30.00. The average price target represents 139.56% Increase from the current price of $22.68.

What do analysts say about Definium Therapeutics, Inc.?

Definium Therapeutics, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 12 Wall Streets Analysts.

How can I buy shares of DFTX?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Definium Therapeutics (DFTX) Stock Forecast & Price Target

DFTX Analyst Ratings

DFTX Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Definium Therapeutics

DFTX Analyst Recommendation Trends

DFTX Financial Forecast

DFTX Earnings Forecast

DFTX Sales Forecast

DFTX Stock Forecast FAQ

Detailed List of Analyst Forecasts